CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
Enzastaurindrug
Likely dose
Enzastaurin 1125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00718419
NCT00718419Phase 2Completed
CompareCT.gov

An Open Label, Multicenter Phase 2 Study of Single-Agent Enzastaurin HCl in Previously Treated Waldenstrom's Macroglobulinemia or Multiple Myeloma

Eli Lilly and Company·interventional·Posted Jul 18, 2008·Updated Sep 3, 2020

In Brief

A Phase 2 clinical trial evaluating Enzastaurin for Waldenstrom's Macroglobulinemia and Multiple Myeloma. Completed, enrolled 56 participants across 4 sites in 2 countries.

Detailed Summary

To determine whether further study of single-agent enzastaurin is warranted in patients with previously treated Waldenstrom's Macroglobulinemia or Multiple Myeloma based on response.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWaldenstrom's Macroglobulinemia, Multiple Myeloma
CountriesFrance, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 18, 2008
Enrollment StartJul 1, 2008
Primary CompletionSep 1, 2010
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 18.0 years ago

Interventions

Enzastaurindrug

Enzastaurin: Cycle 1 Day 1 only: 3, 125-milligrams (mg) tablets three times on Day 1 (Day 1 total dose = 1125 mg) Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days. Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression.